

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
06 September 2024 (06.09.2024)



(10) International Publication Number  
**WO 2024/180283 A1**

(51) International Patent Classification:

C12N 15/86 (2006.01) A61P 35/00 (2006.01)  
A61K 35/76 (2015.01)

(21) International Application Number:

PCT/FI2024/050082

(22) International Filing Date:

01 March 2024 (01.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20235248 01 March 2023 (01.03.2023) FI  
63/449,116 01 March 2023 (01.03.2023) US

(71) Applicant: **TILT BIOTHERAPEUTICS OY** [FI/FI]; c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI).

(72) Inventors: **HEMMINKI, Akseli**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **CERVERA-CARRASCON, Victor**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **KALERVO, Aino**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **SORSA, Suvi**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI). **SANTOS, João Manuel**; c/o TILT Biotherapeutics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI).

(74) Agent: **LAINE IP OY**; Porkkalankatu 24, 00180 Helsinki (FI).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2024/180283 A1

(54) Title: NOVEL DOSAGE REGIMEN FOR AN ONCOLYTIC ADENOVIRAL VECTOR

(57) Abstract: According to an example aspect of the present invention, there is provided an oncolytic adenoviral vector coding for at least TNFalpha and/or IL-2 for use in treatment of cancer, wherein the adenoviral vector is to be administered to a subject in an active treatment cycle at least three times, preferably at least 5, 6 or 7 times; and wherein at least one, preferably the first, administration is a systemic administration, wherein said active treatment cycle preferably does not include administration of an adoptive cell therapeutic composition comprising TILs or administration of an immune checkpoint inhibitor.